MedTrace Logo

Pharmacological Preparation of the Cervix for Hysteroscopy

NCT05783479 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2023-03-24

No results posted yet for this study

Summary

Pain accompanying office hysteroscopy is the most common reason for its discontinuation. Urogenital atrophy may cause technical difficulties in passage through the cervical canal, further increasing the pain. The aim was to evaluate the effectiveness of vaginal estradiol and hyaluronic acid to facilitate diagnostic hysteroscopy in peri- and postmenopausal women.

Conditions

  • Uterine Polyp
  • Uterine Bleeding
  • Endometrium; Senility

Interventions

DRUG

estradiol

estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure

DRUG

Hyaluronic acid

hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Robert Jach, Prof. · Jagiellonian University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-12-30
Completion
2023-01-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05783479 on ClinicalTrials.gov